Our ON-BOARD™ platform has the capability to improve upon current clinically relevant modalities such as antibody drug conjugates by enabling more precise tumor targeting and broader applicability that is not limited by tumor associated antigens. With this unique platform for oncology drug development we are creating a pipeline of assets both internally and in conjunction with our partners.